Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q6DKJ4

UPID:
NXN_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q6DKJ4; B4DXQ0; D3DTH2; Q3SWW6; Q6P3U6; Q7L4C6; Q9H9Q1

BACKGROUND:
Nucleoredoxin functions as a critical modulator in cellular signaling, specifically inhibiting the Wnt pathway through a redox-dependent mechanism. This action is vital for preventing inappropriate activation of Wnt signaling, which is crucial for cell fate determination, proliferation, and migration. Additionally, its regulatory role over protein phosphatase 2A (PP2A) further establishes its importance in maintaining cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Given its crucial role in the pathogenesis of Robinow syndrome, autosomal recessive 2, Nucleoredoxin presents as a promising target for therapeutic intervention. The protein's involvement in this genetic disorder, characterized by profound skeletal malformations, positions it as a key candidate for the development of targeted therapies. Exploring Nucleoredoxin's function offers a pathway to novel treatment options for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.